20 June 2023 - Akebia Therapeutics today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorisation for Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of symptomatic anaemia associated with chronic kidney disease in adults on chronic maintenance dialysis.

The Swissmedic approval of Vafseo is based on data from a comprehensive development program that included over 7,500 patients, including the global Phase 3 clinical program of vadadustat for the treatment of anaemia due to chronic kidney disease in adult patients on dialysis (INNO2VATE).

Read Akebia Therapeutics press release